David E. Schaffer Ph.D.
Net Worth
Last updated:
What is David E. Schaffer Ph.D. net worth?
The estimated net worth of Dr. David E. Schaffer Ph.D. is at least $9,352,480 as of 22 Oct 2021. He owns shares worth $5,875,922 as insider, has earned $3,043,038 from insider trading and has received compensation worth at least $433,520 in 4D Molecular Therapeutics, Inc..
What is the salary of David E. Schaffer Ph.D.?
Dr. David E. Schaffer Ph.D. salary is $108,380 per year as Co-Founder, Chief Scientific Advisor & Independent Director in 4D Molecular Therapeutics, Inc..
How old is David E. Schaffer Ph.D.?
Dr. David E. Schaffer Ph.D. is 55 years old, born in 1970.
What stocks does David E. Schaffer Ph.D. currently own?
As insider, Dr. David E. Schaffer Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | Co-Founder, Chief Scientific Advisor & Independent Director | 901,215 | $6.52 | $5,875,922 |
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
David E. Schaffer Ph.D. insider trading
4D Molecular Therapeutics, Inc.
Dr. David E. Schaffer Ph.D. has made 7 insider trades in 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,900 units of FDMT stock worth $58,892 on 22 Oct 2021.
The largest trade he's ever made was exercising 22,820 units of FDMT stock on 21 Oct 2021. As of 22 Oct 2021 he still owns at least 901,215 units of FDMT stock.
4D Molecular Therapeutics key executives
4D Molecular Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. David E. Schaffer Ph.D. (55) Co-Founder, Chief Scientific Advisor & Independent Director
- Dr. David H. Kirn (62) Co-Founder, Chief Executive Officer, Pres & Director
- Dr. John F. Milligan (64) Executive Chairman
- Dr. Robert S. Fishman (63) Chief Medical Officer & Therapeutic Area Head of Pulmonology
- Mr. August J. Moretti Esq., J.D. (74) Chief Financial Officer